Amikacin for Horses: Uses, Dosing & Side Effects

This information is for educational purposes only. Never give your pet any medication without your veterinarian's guidance. Dosing, frequency, and safety depend on your pet's specific health profile.

Amikacin is a prescription aminoglycoside antibiotic used in horses for serious bacterial infections. It is especially valued when your vet is concerned about aerobic gram-negative bacteria and in some cases resistant organisms. In equine practice, it may be given intravenously for whole-body treatment or used locally by your vet in places like a joint, uterus, or a limb perfusion setup.

This medication is not absorbed well by mouth, so it is generally used as an injectable drug. In adult horses, intravenous dosing is common because intramuscular injections can be irritating. Your vet may also choose amikacin when culture and susceptibility testing suggest it is a good match for the bacteria involved.

Amikacin can be very useful, but it also needs respect. Like other aminoglycosides, it carries a meaningful risk of kidney injury, especially in dehydrated horses, horses with existing kidney disease, or horses receiving other nephrotoxic drugs. That is why your vet may recommend bloodwork, hydration support, and sometimes drug-level monitoring during treatment.

Your vet may use amikacin for serious bacterial infections such as septic arthritis, osteomyelitis, deep wound infections, pneumonia, pleuropneumonia, some uterine infections, and neonatal foal sepsis. It is commonly chosen when a horse needs strong early coverage while culture results are pending, or when testing shows susceptibility to amikacin.

In horses, amikacin is often part of a broader treatment plan, not a stand-alone answer. For example, a horse with a joint infection may need joint lavage, imaging, anti-inflammatory medication, and repeated reassessment. A foal with sepsis may need IV fluids, plasma, nursing support, and hospitalization in addition to antibiotics.

Your vet may also use amikacin locally to achieve high concentrations at the infection site. Common examples include intra-articular injection for infected synovial structures, regional limb perfusion for lower-limb infections, and intrauterine administration in selected mares. These routes can be helpful because they deliver more drug where it is needed while sometimes limiting whole-body exposure.

Amikacin dosing in horses depends on the horse's age, hydration status, kidney function, infection site, and route of administration. Published equine references commonly list adult horses at 10 mg/kg IV every 24 hours and foals at 20-25 mg/kg IV every 24 hours. Merck also notes neonatal foals may need age-specific adjustments, and therapeutic drug monitoring is recommended in higher-risk patients.

For some localized infections, your vet may use amikacin by regional limb perfusion, intra-articular injection, or intrauterine infusion rather than systemic dosing. Merck lists an intrauterine dose of 1-2 g in mares, while local joint or limb-perfusion protocols vary by case, anatomy, and clinician preference. These are procedures for your vet, not something to attempt at home.

Because aminoglycosides are concentration-dependent antibiotics, once-daily dosing is often preferred. If kidney function is reduced, your vet will usually adjust the dosing interval rather than lowering the dose too much, so the drug can still reach effective peak levels. Expect your vet to consider baseline creatinine, hydration, urine output, and sometimes peak/trough levels if treatment will continue for several days or the horse is medically fragile.

Never change the dose or frequency on your own. If a dose is missed, the horse seems dull, stops drinking, urinates abnormally, or has worsening signs of infection, contact your vet promptly for guidance.

The most important side effect with amikacin is kidney toxicity. This risk rises in horses that are dehydrated, critically ill, already have kidney disease, or are receiving other drugs that can stress the kidneys. Early warning signs can be subtle, which is why your vet may recommend repeat bloodwork even if your horse seems stable.

Possible signs that deserve a call to your vet include decreased appetite, lethargy, reduced water intake, increased thirst, changes in urination, or worsening illness despite treatment. Merck notes that aminoglycoside nephrotoxicity may be associated with polyuria, decreased urine concentrating ability, protein in the urine, and rising kidney values on lab work.

Other concerns include muscle irritation with intramuscular injection, rare neuromuscular weakness, and local tissue irritation when the drug is used in specialized procedures. In joints, there is also ongoing discussion in equine medicine about dose-related irritation and cartilage effects with intra-articular antibiotic use, so your vet will weigh the benefits and risks carefully.

See your vet immediately if your horse becomes weak, stops eating, seems dehydrated, develops severe diarrhea, or shows signs that the original infection is getting worse. Fast reassessment matters more than trying to guess whether the medication is the cause.

Amikacin should be used carefully with other nephrotoxic or ototoxic medications. In equine patients, the most practical concern is combining it with drugs that can add kidney stress, such as NSAIDs in a dehydrated or compromised horse, other aminoglycosides, or amphotericin B. Your vet may still use combinations when needed, but only with a clear monitoring plan.

Loop diuretics such as furosemide can also increase concern for toxicity in some settings, especially if the horse is not well hydrated. If your horse is receiving IV fluids, anti-inflammatories, antifungals, or multiple antibiotics, make sure your vet knows every medication and supplement being given.

There can also be practical compatibility issues when injectable drugs are mixed or administered through the same line. Because of that, amikacin should only be prepared and administered exactly as your vet directs. If your horse has a history of kidney disease, prior aminoglycoside exposure, or recent hospitalization, mention that before treatment starts.